Metaloproteinasa de la matriz 9 cervicovaginal en el segundo trimestre para la predicción de parto pretérmino

Abstract

Objective

To establish the prognostic usefulness of cervicovaginal fluid concentrations of matrix metalloproteinase-9 in the second trimester for the prediction of preterm delivery.

Materials and method

A case-control study was conducted on 613 pregnant women attending the Dr. Urquinaona Central Hospital, Maracaibo, Venezuela. Group A (n = 52) women with preterm birth and group B (n = 561) women with term birth, (control group) of pregnant women who had term deliveries. The cervicovaginal concentrations of matrix metalloproteinase-9 were compared between the 2 groups.

Results

The mean gestation age at measurement of cervicovaginal concentrations of matrix metalloproteinase-9 was 26.2 ± 1.1 weeks in Group A, and 25.9 ± 1.1 weeks in Group B (P = ns). There were no significant differences in maternal age, body mass index, or history of pre-term labour. Cervicovaginal matrix metalloproteinase-9 concentrations were higher in Group A (252.6 ± 104.1 ng/mL) than in Group B (214.7 ± 120.9 ng/mL; P< .0285). A cut-off value of 180 ng/mL had an under the curve value of 0.59, with a sensitivity of 75.0%, specificity of 41.1%, positive predictive value of 10.5%, and negative predictive value of 94.6%.

Conclusion

Cervicovaginal matrix metalloproteinase-9 concentrations in second trimester are elevated in pregnant women, who later had pre-term delivery, but are not useful for predicting this.